ABSTRACT
Wastewater surveillance has emerged as a crucial public health tool for population-level pathogen surveillance. Supported by funding from the American Rescue Plan Act of 2021, the FDA’s genomic epidemiology program, GenomeTrakr, was leveraged to sequence SARS-CoV-2 from wastewater sites across the United States. This initiative required the evaluation, optimization, development, and publication of new methods and analytical tools spanning sample collection through variant analyses. Version-controlled protocols for each step of the process were developed and published on protocols.io. A custom data analysis tool and a publicly accessible dashboard were built to facilitate real-time visualization of the collected data, focusing on the relative abundance of SARS-CoV-2 variants and sub-lineages across different samples and sites throughout the project. From September 2021 through June 2023, a total of 3,389 wastewater samples were collected, with 2,517 undergoing sequencing and submission to NCBI under the umbrella BioProject, PRJNA757291. Sequence data were released with explicit quality control (QC) tags on all sequence records, communicating our confidence in the quality of data. Variant analysis revealed wide circulation of Delta in the fall of 2021 and captured the sweep of Omicron and subsequent diversification of this lineage through the end of the sampling period. This project successfully achieved two important goals for the FDA’s GenomeTrakr program: first, contributing timely genomic data for the SARS-CoV-2 pandemic response, and second, establishing both capacity and best practices for culture-independent, population-level environmental surveillance for other pathogens of interest to the FDA.
IMPORTANCE This manuscript serves two primary objectives. Firstly, it summarizes the genomic and contextual data collected during a Covid-19 pandemic response project, which utilized the FDA’s laboratory network, traditionally employed for sequencing foodborne pathogens, for sequencing SARS-CoV-2 from wastewater samples. Secondly, it outlines best practices for gathering and organizing population-level Next Generation Sequencing (NGS) data collected for culture-free, surveillance of pathogens sourced from environmental samples.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The American Rescue Plan Act of 2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵7 GenomeTrakr laboratory consortium group of authors
Emails: Ruth.Timme{at}fda.hhs.gov, Jacquelina.Woods{at}fda.hhs.gov, Jessica.Jones{at}fda.hhs.gov, Kevin.Calci{at}fda.hhs.gov, Rachel.Rodriguez{at}fda.hhs.gov, cndc.brns93{at}gmail.com, Elizabeth.Leard{at}fda.hh, Mark.Craven{at}fda.hhs.gov, Haifeng.Chen{at}fda.hhs.gov, Cameron.Boerner{at}fda.hhs.gov, Christopher.Grim{at}fda.hhs.gov, Amanda.Windsor{at}fda.hhs.gov, Padmini.Ramachandran{at}fda.hhs.gov, Tim.Muruvanda{at}fda.hhs.gov, Hugh.Rand{at}fda.hhs.gov, Bereket.Tesfaldet{at}fda.hhs.gov, jamirzadegan{at}gmail.com, tkayikci{at}gmx.com, tmwalsky{at}gmail.com, Marc.Allard{at}fda.hhs.gov, Maria.Balkey{at}fda.hhs.gov, Candace.Bias{at}fda.hhs.gov, Eric.Brown{at}fda.hhs.gov, Kathryn.Judy{at}fda.hhs.gov, Tina.Pfefer{at}fda.hhs.gov, Sandra.Tallent{at}fda.hhs.gov, Maria.Hoffmann{at}fda.hhs.gov, James.Pettengill{at}fda.hhs.gov
Data Availability
SARS-CoV-2 sequence data + contextual data collected through this project are available under the NCBI BioProject, PRJNA757291. Variant analysis results are available through links posted on our dashboard: https://www.fda.gov/food/whole-genome-sequencing-wgs-program/wastewater-surveillance-sars-cov-2-variants or through.
